Metabolic Contrasts: Fatty Acid Oxidation and Ketone Bodies in Healthy Brains vs. Glioblastoma Multiforme.
Level 5 - mechanism / opinion, no new human data
Narrative review of metabolic pathways and mechanisms without original empirical data
PubMed 38791520 · doi:10.3390/ijms25105482
What was done
This narrative review summarizes the key enzymes, transporters (such as FAT, FABP, and FATP), and regulatory pathways of fatty acid oxidation and ketone body utilization, comparing normal brain physiology with metabolic alterations in glioblastoma multiforme.
What was found
The abstract outlines baseline epidemiology (glioblastoma represents 45.6% of primary malignant brain tumors, with an incidence of 3.1 per 100,000) and characterizes tumor metabolic reprogramming, including the Warburg effect and the overexpression of specialized fatty acid transporters that support lipid accumulation for growth and invasion. No primary experimental numbers or effect sizes are reported in the abstract.
Why it matters
Clarifying how glioblastoma cells switch lipid and ketone metabolism relative to healthy brain tissue highlights metabolic vulnerabilities that could be exploited for novel targeted therapies.
Limits
As a narrative review, it presents no original clinical trial or laboratory data and does not employ systematic review methodology. Specific comparative quantitative metrics, sample sizes, and therapeutic efficacy data are absent from the abstract.
Cited by
- contradicts Cancer cells cannot metabolize fatty acids or ketone bodies for energy because of defective mitochondrial structure and function.